CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1(G93A) mice with a C57BL/6 background

The synthetic copper-containing compound, CuATSM, has emerged as one of the most promising drug candidates developed for the treatment of amyotrophic lateral sclerosis (ALS). Multiple studies have reported CuATSM treatment provides therapeutic efficacy in various mouse models of ALS without any obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Lum, Jeremy S., Brown, Mikayla L., Farrawell, Natalie E., McAlary, Luke, Ly, Diane, Chisholm, Christen G., Snow, Josh, Vine, Kara L., Karl, Tim, Kreilaus, Fabian, McInnes, Lachlan E., Nikseresht, Sara, Donnelly, Paul S., Crouch, Peter J., Yerbury, Justin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481268/
https://www.ncbi.nlm.nih.gov/pubmed/34588483
http://dx.doi.org/10.1038/s41598-021-98317-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481268/
https://www.ncbi.nlm.nih.gov/pubmed/34588483
http://dx.doi.org/10.1038/s41598-021-98317-w

Ejemplares similares